<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the efficacy of epigallocatechin <z:chebi fb="0" ids="16918">gallate</z:chebi> (<z:chebi fb="0" ids="4806">EGCG</z:chebi>) for improving function in rats with transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="1" pm="."><plain>Three procedures underwent for each groups; MCAO and <z:chebi fb="0" ids="4806">EGCG</z:chebi> treatment, MCAO without treatment (MCAO control), and sham operation </plain></SENT>
<SENT sid="2" pm="."><plain>Function was evaluated on days 1, 5, 10, and 14 after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, using a modified sticky-tape test and the percentage weight borne on the paretic leg </plain></SENT>
<SENT sid="3" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume did not differ between the <z:chebi fb="0" ids="4806">EGCG</z:chebi>-treated and MCAO control groups </plain></SENT>
<SENT sid="4" pm="."><plain>Compared with the MCAO control group, the <z:chebi fb="0" ids="4806">EGCG</z:chebi>-treated group showed improved forelimb function and had <z:mpath ids='MPATH_458'>normal</z:mpath> function by day 10 (P&lt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The improvements persisted until day 14 postischemia </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, hind limb function did not differ between the <z:chebi fb="0" ids="4806">EGCG</z:chebi>-treated and MCAO control groups </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, <z:chebi fb="0" ids="4806">EGCG</z:chebi> improved certain aspects of function of forelimb until day 14 after MCAO in rats </plain></SENT>
</text></document>